Prime Medicine Inc

Prime Medicine, Inc. operates as a biotechnology company. It develops one-time curative genetic therapies, Prime Editors to address the wide spectrum of diseases by deploying its Prime Editing technology. The company was founded by David R. Liu on September 13, 2019 and is headquartered in Cambridge, MA.

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Prime Medicine, Inc. is a biotechnology company, which engages in developing one-time curative genetic therapies. The company was founded by David R. Liu on September 13, 2019 and is headquartered in Cambridge, MA.

New In Vivo Data in Humanized Mouse Model Demonstrate that Prime Editing Can Correct Predominant Mutations Accounting for Approximately 60% of Patients with RHO adRP Up to 70% Precise Correction at RHO p.P23H Mutation and up to 65% at RHO p.V345L and p.P347L, Well Above Threshold Required to Stop Disease Progression in Photoreceptors No Detectable AAV Genome Integration and No Detectable Off-target Edits Observed Data Presented Today in an Oral Presentation at RD2023 CAMBRIDGE, Mass., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated, one-time curative genetic therapies, today reported new preclinical data demonstrating the ability of Prime Editors to efficiently and precisely correct the predominant mutations that cause rhodopsin associated autosomal dominant retinitis pigmentosa (RHO adRP).

Prime Medicine Presents First In Vivo Proof-of-Concept Prime Editing Data Demonstrating Ability of Prime Editors to Treat Ophthalmological Diseases

Arcellx

Apogee Therapeutics Inc

CRISPR Therapeutics

Immunome

Nuvalent

Vir Biotechnology

Biotechnology is the source of some of our strongest and growing revolutions. Gene technology allows us to cure incurable diseases and make miracles happen with living organisms.

7 Biotech Stocks to Get In Now Before Investors Catch On

CAMBRIDGE, Mass., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that the Company will showcase advances in preclinical data across the Prime Editing pipeline and platform at several healthcare industry conferences in October and November 2023.

Prime Medicine to Highlight Positive Preclinical Developments Across Prime Editing Pipeline and Platform at Upcoming Industry Conferences

Prime Medicine is developing prime editing, a highly precise gene editing technology that offers advantages over traditional CRISPR-Cas9 gene editing. Prime editing has shown promising results in human cell lines, including correcting genetic causes of diseases. The company's lead program is focused on Chronic Granulomatous Disease (CGD), a rare genetic disorder that affects the immune system.

Prime Medicine: Not Yet Primed For Retail Investment

-- Presented new preclinical data demonstrating ability of Prime Editing to correct causative mutation of CGD and highlighting ability of PASSIGE™ platform to multiplex edit CAR-T cells at ASGCT Annual Meeting -- -- Entered strategic collaboration with Cimeio Therapeutics; multiplexing Cimeio's shielded variants with therapeutic edits may meaningfully expand reach of Prime Editing --

Prime Medicine Reports Second Quarter 2023 Financial Results and Provides Business Updates

Ginkgo Bioworks Holdings

Cathie Wood has positions in several leading genomic medicine companies. Prime Medicine and Ginkgo Bioworks could be two of her fund's biggest winners in the years to come.

2 Cathie Wood Stocks That Could Be Hidden Gems

-- Collaboration combines Prime Medicine's Prime Editing platform with Cimeio Therapeutics' Shielded Cell and Immunotherapy Pairs™ (SCIP™) platform -- -- Aim to reduce toxicity of conditioning regimens and introduce new therapeutic options that can expand the utility of hematopoietic stem cell (HSC) transplant and in vivo genetic therapies --

Prime Medicine and Cimeio Therapeutics Announce Research Collaboration to Develop Prime Edited Shielded-Cell & Immunotherapy Pairs™ for Genetic Diseases, Acute Myeloid Leukemia and Myelodysplastic Syndrome

Adaptive Biotechnologies

CrowdStrike

CrowdStrike, Prime Medicine, and Adaptive Biotechnologies were all on the Ark Invest shopping list on Thursday. CrowdStrike opened 8% lower on Thursday despite a "beat and raise" quarterly report.

Cathie Wood Goes Bargain-Hunting: 3 Stocks She Just Bought

CAMBRIDGE, Mass., May 31, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Keith Gottesdiener, M.D., President and Chief Executive Officer of Prime Medicine, will participate in three investor conferences in June:

Prime Medicine to Present at Investor Conferences in June

CAMBRIDGE, Mass., May 17, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Keith Gottesdiener, M.D., President and Chief Executive Officer of Prime Medicine, will present at two virtual investor conferences in May:

Prime Medicine to Present at Virtual Investor Conferences in May

Data demonstrated Prime Editors efficiently, reproducibly and durably corrected the causative mutation of CGD, supporting advancement of development candidate PM359

Prime Medicine to Present New Preclinical Data Highlighting Broad Potential of Prime Editing Technology at ASGCT 26th Annual Meeting

-- New data further demonstrating ability of Prime Editing to correct causative mutation of CGD and highlighting potential of PASSIGE platform to multiplex edit CAR-T cells to be presented at ASGCT Annual Meeting -- -- Expanded Board of Directors with appointment of Jeff Marrazzo, former CEO of Spark Therapeutics --

Prime Medicine Reports First Quarter 2023 Financial Results and Provides Business Updates

Prime Medicine: Gene Editing Tech With Unique Approach.

Prime Medicine: Gene Editing Tech With Unique Approach

CAMBRIDGE, Mass., March 27, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Keith Gottesdiener, M.D., President and Chief Executive Officer of Prime Medicine, will present a corporate overview at the Guggenheim Healthcare Talks – Genomic Medicines and Rare Disease Days on Monday, April 3, 2023 at 3:55 p.m. ET in New York, NY.

Prime Medicine to Present at Guggenheim Healthcare Talks – Genomic Medicines and Rare Disease Days

-- Announced preclinical data providing further proof-of-concept for Prime Editing's ability to achieve restoration of genetic function, as well as new preliminary safety analyses demonstrating no detected off-target activity -- -- Nominated PM359, first development candidate for the treatment of Chronic Granulomatous Disease (CGD) --

Prime Medicine Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

CAMBRIDGE, Mass., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Keith Gottesdiener, M.D., President and Chief Executive Officer of Prime Medicine, will present a corporate overview at the Cowen 43rd Annual Health Care Conference on Monday, March 6, 2023 at 9:50 a.m. ET in Boston, MA.

Prime Medicine to Present at Cowen 43rd Annual Health Care Conference

CRISPR Therapeutics is probably the most widely-known company utilizing the original CRISPR-Cas9 gene editing method. Prime editing is a newer variation on CRISPR-Cas9 which is safer since it doesn't produce double-strand breaks in DNA.

Prime Medicine 'Crispr 3.0' Vs. Crispr Therapeutics

AbCellera Biologics

AST SpaceMobile

Beam Therapeutics

Editas Medicine

JFrog

HashiCorp

Maxar Technologies

MongoDB

Intellia Therapeutics

UiPath

Planet Labs

Rocket Lab USA

Sumo Logic

Tesla

While others flock to safety, should you do the opposite? Some of the best times to invest in highly speculative names are when no one wants them, as long as the reasons are macro and not company or industry specific.

10 Potential 10x Return Stocks For The Next 10 Years

CAMBRIDGE, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Keith Gottesdiener, M.D., President and Chief Executive Officer of Prime Medicine, will present a corporate overview at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 at 8:15 a.m. PT (11:15 a.m. ET) in San Francisco, CA.

Prime Medicine to Present at 41st Annual J.P. Morgan Healthcare Conference

Prime Medicine's technology originated at Harvard/MIT and has been termed as CRISPR 3.0. Beam Therapeutics partnership in sickle cell disease and the experienced management add confidence in the Prime Editing technology.

Prime Medicine: CRISPR 3.0 Company

CAMBRIDGE, Mass., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the closing of its upsized initial public offering of 10,294,118 shares of its common stock at a price to the public of $17.00 per share. The gross proceeds of the offering were approximately $175.0 million, before deducting underwriting discounts and commissions and other offering expenses. In addition, Prime Medicine has granted the underwriters a 30-day option to purchase up to an additional 1,544,117 shares of its common stock at the initial public offering price less underwriting discounts and commissions. The shares began trading on the Nasdaq Global Market on October 20, 2022 under the ticker symbol “PRME.” All shares in the offering were offered by Prime Medicine.

Prime Medicine Announces Closing of Upsized Initial Public Offering

Prime Medicine Inc, a biotechnology company specializing in gene editing, debuted on the Nasdaq Thursday after pricing one of the year's largest IPOs in the sector.  The Cambridge, Massachusetts-based company priced an upsized 10,294,118 shares of common stock at a public price of $17 each, good for expected gross proceeds of $175 million.

Gene-editing firm Prime Medicine slips in Nasdaq debut following big biotech IPO

Prime Medicine (NASDAQ: PRME ) stock is catching the interest of traders on Thursday as the company launches its initial public offering (IPO) today! The company is launching an upsized offering that includes 10,294,118 shares of PRME stock priced at $17 each.

Is Prime Medicine (PRME) Stock the Next Hot IPO?

Prime Medicine Announces Pricing of Upsized Initial Public Offering

Prime Medicine has filed proposed terms for a $151 million U.S. IPO. The firm is a pre-clinical stage biopharma developing genetic treatments for a wide variety of diseases.

IPO Update: Prime Therapeutics Readies $151 Million U.S. IPO

News for Prime Medicine Inc Stock (PRME)